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Abstract 
Texaphyrins are a synthetic class of porphyrin analogues that contain a metal 
atom complexed at their centers.  This class of compounds selectively accumulates in 
cancer cells, thus creating a promising opportunity for medicinal chemists to synthesize 
novel anti-cancer agents.  Texaphyrins may become especially valuable as anti-cancer 
agents by synthetically including atoms such as gadolinium and boron into their 
structures.  The presence of either of these 
elements allows the compounds to be used in 
Neutron Capture Therapy (NCT), a non-invasive 
experimental treatment procedure for cancer.  
While texaphyrins are promising novel agents 
for use in oncology, better synthetic methods for 
developing and optimizing these compounds are still 
needed.  The purpose of this study is to find effective synthetic methods for the 
development of a texaphyrin that could be used in cancer therapy and diagnosis.  Two 
such gadolinium- and boron-containing texaphyrins (GdB-texaphyrins) have already 
been successfully synthesized in our laboratories and are currently undergoing pre-
clinical trials.  This project has accomplished the synthesis of the direct pre-cursor to a 
specific GdB-texaphyrin (pictured on this page), and the compound’s complete 
synthesis will continue to be pursued in our laboratories. This study has therefore 
provided valuable data about the pursued synthetic pathway to help researchers 
continue to advance the synthesis of this novel class of anti-cancer agents.  
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Introduction 
Texaphyrins are large, macrocyclic compounds that contain a lanthanide metal 
atom complexed at their centres. This class of compounds selectively accumulates in 
cancer cells1, and our synthesis of texaphyrins attempts to equip them with the 
necessary means to be used in cancer diagnosis and treatment.   
This is accomplished by the inclusion of gadolinium and boron into the 
texaphyrin.  The presence of boron and/or gadolinium allows the compound to be used 
as the chemical agent in Neutron Capture Therapy (NCT), a non-invasive, chemo-
radiotherapeutic modality for the treatment brain tumors2. NCT involves exposing boron- 
and/or gadolinium-infused tumour cells to neutrons.  Both elements and the neutrons 
are alone harmless to biological tissue, but form lethal particles and radiation that easily 
kill cells when they come in contact with each other.  It is important to NCT that both 
boron and/or gadolinium accumulate only in tumour cells so that the tumour will be 
destroyed while nearby healthy tissue is left unharmed.  This can be accomplished by 
linking these elements to texaphyrins, since they selectively accumulate in tumour 
tissue but not in healthy tissue.   
The presence of gadolinium in these compounds also allows their distribution in 
living tissue to be determined by Magnetic Resonance Imaging (MRI), thus making 
these compounds also useful to the diagnosis of cancer.  Texaphyrins may also have 
potential uses in other cancer treatment and diagnostic procedures, such as Near 
Infrared Imaging1.  
Structurally, texaphyrins are expanded porphyrin-like compounds that contain a 
metal atom at their center (in this case gadolinium) surrounded by one benzene unit and 
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three pyrrole units. There are several 
possibilities to incorporate boron into these 
compounds. In principle, texaphyrins contain 
four possible subunits (α,
 
β, γ, δ) that can 
contain boron (see figure). In this project, we 
chose to bind a carborane cluster, containing ten 
boron atoms, to an aromatic aldehyde (used as 
the “β” subunit), which is then used to connect the benzene and pyrrole units of the 
texaphyrin.  Previously synthesized GdB-texaphyrins that have included the boron-rich 
carborane cages at the α2 subunit are now being tested in our collaborator’s lab for their 
chemical and biological properties. 
 The aforementioned carborane clusters have been the preferred boron moieties 
in BNCT compound development because of their chemically modifiable nature, 
structural and physicochemical versatility, high boron content, and stability3. Each 
cluster contains ten boron atoms and two carbon atoms arranged in an ortho, meta, or 
para conformation (see figure below).  After preliminary attempts at the synthesis using 
ortho-carborane and previous experience using para-carborane, it was decided that 
meta-carborane would be used in this 
project.  Meta-carborane appeared to afford 
the highest-yielding reactions in this 
synthesis, presumably due to it being more 
stable than the ortho isomer and also 
having a somewhat lower potential to 
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create dimers than the para isomer.  
The two boron-containing compounds that are currently being used as chemical 
agents in BNCT are boronphenylalanine (BPA) and sodium borocaptate (BSH)2 
(structures at right). BNCT has been successful in 
shrinking tumors using these agents, but better agents 
need to be synthesized2,5. Challenges in synthesizing 
better BNCT agents include achieving improved tumor 
selectivity and sufficient boron concentrations within 
tumors, estimated to be ~20 µg/g tumor2, while avoiding 
systemic toxicity.  GdB-Texaphyrins have the potential to 
be better BNCT agents because they contain more boron per molecule, show excellent 
tumor specificity, and exhibit low system toxicity1.  
 
Specific Aim 
The specific aim of this project is to further develop synthetic strategies to generating 
GdB-texaphyrins that can be used in cancer therapy and diagnostics.  
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Synthetic Strategies 
The starting material, p-(bromomethyl)benzonitrile, is commercially available (compound A).  
p-(Bromomethyl)benzonitrile (A) is oxidized to an aldehyde (B) using DIBAL-H 
(diisobutylaluminum hydride).  The aldehyde function is then protected as an acetal (C) so 
that the boron moiety can be incorporated. meta-Carborane is introduced in the next step by 
substituting bromine (D). The acetal protective group is then removed, forming the 
carboranyl “aldehyde precursor” (E).  
 
Scheme 1: Precursor Synthesis: 
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Then, a “pyrrole trimer” (F) is generated. It consists of two “aldehyde precursors” (E) and 
three pyrrole units. This was specified at the beginning of the project as the target 
molecule (F). A Vilsmeier-Haack reaction is then performed to formylate the two available 
pyrrole units (G).  The formylating agent is formed in situ from DMF and oxalyl chloride, 
and forms an α-chloro amine with the available pyrrole units via electrophilic aromatic 
substitution. The amine is then rapidly hydrolyzed during workup to give the aldehyde (G). 
A Schiff base reaction is then performed to “cyclize” the molecule (this is a relatively 
unstable intermediate) (H).  Finally, the gadolinium is complexed at the molecule’s center, 
creating the GdB-texaphyrin (I). 
Scheme 2: Cyclization Synthesis 
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The theoretical spectrum (above left) shows the  
dominant peak at about molecular weight 712.6,  
and our sample (right) generated its dominant peak  
at molecular weight 713.7. 
 
The theoretical spectrum was generated using “Isotope Pattern Calculator 
v4.0,” developed by Junhua Yan. 
 
Results and Discussion 
Compound B was generated in ~90% yields after purification via column 
chromatography with hexane and ethyl acetate in a 9:1 ratio.  Crude compound C was 
obtained in high yields, and was used in the next step without further purification to 
avoid premature de-protection of the aldehyde.  
Compound D was obtained in approximately 45% yield, and was de-protected to 
compound E without further purification due to the propensity of the acetal group to de-
protect during purification. This resulted in a total yield of approximately 34% for the C-E 
synthetic steps.  Several aliquots of Compound E from multiple reaction runs were 
collectively purified via column chromatography and then characterized via 1H NMR, 13C 
NMR, and mass spectrometry. 
Compound F was believed to be generated in 25% yield as purple crystals, but 
with an impurity that made it difficult to retrieve conclusive Nuclear Magnetic Resonance 
(NMR) spectra. The theoretical (left) and actual (right) mass spectra of compound F are 
below. They are very similar and so we proceeded with the synthesis under the 
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The theoretical spectrum (above left) shows the 
dominant peak at about molecular weight 457.3, 
and our sample (right) generated its dominant 
peak at molecular weight 457.3. 
 
The theoretical spectrum was generated using 
“Isotope Pattern Calculator v4.0,” developed by 
Junhua Yan. o B9H9
BH
NH
NH
CHO
CHO
assumption that the “pyrrole trimer” had been synthesized. When the synthesis of 
compound G was attempted, however, dimeric pyrrole di-aldehyde was found to be 
predominantly formed instead of the target trimeric pyrrole di-aldehyde, and in 13% 
yield. The NMR data for both compound F and compound G was difficult to interpret 
due to impurities, however, mass spectroscopy data was more helpful in characterizing 
these compounds. 
The structure and corresponding mass spectra of the proposed “dimeric pyrrole 
di-aldehyde” are shown below. It is postulated that the impurity noted in the trimerization 
reaction (the formation of compound F) was a pyrrole dimer, instead of the target trimer 
(F).  It is also believed that the reaction conditions of the following step (the formation of 
compound G) favored the formylation of the dimer over that of the trimer, resulting in the 
dimeric pyrrole di-aldehyde (shown below) being the dominant product formed instead 
of the target trimeric pyrrole di-aldehyde (compound G).   
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Future attempts to complete this synthesis should focus on diligently purifying the 
“pyrrole trimer” (compound F), and on adjusting reactant ratios in the following reaction 
to favor the formation of the trimeric pyrrole di-aldehyde (compound G), instead of the 
dimeric pyrrole di-aldehyde that predominated. 
 
Conclusion and Outlook 
Two novel GdB-texaphyrins have already been synthesized in our laboratories 
and are currently undergoing pre-clinical trials. This project has accomplished the 
synthesis of pre-cursors to a specific GdB-texaphyrin (compound I), and its complete 
synthesis will continue to be pursued in our laboratories.  This will be followed by its 
biological and pre-clinical evaluation. 
 This study has therefore provided valuable data about the pursued synthetic 
pathway to help researchers continue to advance the synthesis of this novel class of 
anti-cancer agents.  
 
Experimental Procedures 
General experimental procedures.  1H-and 13C-NMR spectra were obtained on a 
Bruker 400 MHz FT-NMR instrument. Chemical shifts are reported in parts per million 
(ppm). The coupling constants are reported in Hertz (Hz). Compound visualization on 
Silica Gel 60 F254 pre-coated TLC plates (0.25 mm layer thickness) (Merck, Darmstadt, 
Germany) was attained by UV light. Reagent grade solvents were used for column 
chromatography using Silica gel 60, particle size 0.040-0.063 mm (Merck, New Jersey). 
Anhydrous chlorobenzene and pyrrole and other reagent grade chemicals were 
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obtained from commercial vendors and used as such. Low- and High-resolution 
electrospray ionization (LR- and HR-ESI) mass spectra were recorded on a Micromass 
Q-Tof II electrospray mass spectrometer and a Micromass LCT electrospray mass 
spectrometer at The Ohio State University Campus Chemical Instrumentation Center 
(OSU-CCIC). The theoretical spectra were generated using “Isotope Pattern Calculator 
v4.0,” developed by Junhua Yan. 
 
p-(Bromomethyl)-benzaldehyde (Compound B).  To a stirred solution of p-
(bromomethyl)benzonitrile (3.00 g, 15.3 mmol)  in anhydrous chlorobenzene (50 mL) 
was added a 1M solution of DIBAL-H in hexanes (24.5 mL, 24.5 mmol) over a 20 
minute period at 0°C. The reaction mixture was stirred for 2.5 hours at 0°C, diluted with 
dichloromethane, and treated with a 10% aqueous HCl solution. The reaction mixture 
was then extracted with dichloromethane, and washed with brine. The organic layer was 
dried over Na2SO4, filtered and evaporated. The resulting residue was purified via 
column chromatography with hexane and ethyl acetate in a 9:1 ratio to give the pure 
product in 93% yield (2.83 g). 1H NMR (CDCl3): δ 10.05 (s, 1H, -CHO), δ 7.90 (d, 2H, -
Ph), δ 7.59 (d, 2H, -Ph), δ 4.55 (s, 2H, Br-CH2-Ph)   
 
2-[4-(Bromomethyl)phenyl]-1,3-dioxolane  (Compound C).  A mixture of p-
(bromomethyl)-benzaldehyde (compound B) (1.00 g, 5.2 mmol), ethylene glycol (1.1 
mL, 1.25 g, 20.1 mmol), and a catalytic amount of p-toluenesulfonic acid in toluene (50 
mL) was refluxed in a Dean Stark apparatus for 6 hours. The reaction mixture was then 
cooled to room temperature, extracted with cold water and EtOAc, washed with brine, 
 12 
and dried over Na2SO4. Subsequently, the organic phase was evaporated. The resulting 
crude mixture (1.75 g) was then used in the next step with out purification to avoid 
premature de-protection of the aldehyde. 1H NMR (CDCl3): δ 7.44 (d, 2H, -Ph), δ 7.39 
(d, 2H, -Ph), δ 5.79 (s, 1H, Ph-CH-acetal), δ 4.47 (s, 2H, Br-CH2-Ph), δ 4.05 (m, 4H, 
acetal)    
  
2-[4-(Carboranylmethyl)phenyl]-1,3-dioxolane (Compound D).   To a solution of m-
carborane (2.60 g, 18.0 mmol) in THF (60 mL) was added drop-wise a 2.5 M solution of 
BuLi in hexanes (6.6 mL, 16.5 mmol) at 0°C under anhydrous Ar. The reaction mixture 
was stirred at rt for 1.5 hours. The 2-[4-(bromomethyl)phenyl]-1,3-dioxolane synthesized 
in the previous step (compound C) (3.65 g, 15.0 mmol) was diluted slightly with THF 
before being added to the reaction mixture over a 2 minute period. The reaction mixture 
was then stirred overnight, extracted with ether, and washed with brine. The organic 
phase was dried over Na2SO4, filtered, and evaporated. The resulting residue 
(compound D in approximately 45% yield, 2.07 g) was used in the next reaction without 
further purification (see Results and Discussion).  
 
p-(Carboranylmethyl)-benzaldehyde (Compound E).  Compound D (2.07 g, 6.76 
mmol) was stirred overnight with 1N HCl (6 mL) in THF (60 mL). The reaction mixture 
was then extracted with ether, washed with brine, and dried over Na2SO4. 
Subsequently, the organic phase was evaporated to generate compound E in 91% 
crude yield (1.55 g). Combined portions of this crude product from multiple reaction 
attempts were combined at a later date and purified via column chromatography with 
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hexanes and DCM in a 1:1 ratio to yield pure compound E.  1H NMR (CDCl3): δ 10.03 
(s, 1H, -CHO), δ 7.86 (d, 2H, -Ph), δ 7.30 (d, 2H, -Ph), δ 3.31 (s, 2H, B10H10CHC-CH2-
Ph), δ 2.91 (s, 1H, carborane CH); 13C NMR (CDCl3): δ 191.69 (CHO), δ 143.34 (Ph), δ 
135.57 (Ph), δ 130.56 (Ph), δ 129.83 (Ph), δ 42.77 (CH2); MS (HR-ESI) 
C10H1910B211B8O (M + H) calcd 263.2439, found 263.2321.  
  
Attempted 2,5-Bis-[(4-(carboranylmethyl)phenyl)-(1H-pyrrol-2-yl)-methyl]-1H-
pyrrole (Compound F).  A solution of compound E (0.30 g, 1.2 mmol) and pyrrole (0.42 
mL, 0.40 g, 6.0 mmol) was stirred at rt under anhydrous Ar for 5 minutes. A 5% solution 
of TFA (3 µL) was added slowly and stirring was continued for 15 minutes. The reaction 
mixture was then quenched with 0.5M NaOH (0.1 mL) and dichloromethane before 
being washed three times with water. The organic layer was dried over Na2SO4, filtered, 
and then evaporated. The resulting residue was purified via preparative TLC with 
hexane and ethyl acetate in a 6:1 ratio to give compound F in 28% yield (232 mg). 
Definitive 1H NMR data not obtained (see Results and Discussion). MS (LR-ESI) 
C32H47B20N3 (M + Na) calcd 712.6, found 713.7.  
 
Attempted 1,14-Bisformyl-5,10-di[4-(carboranylmethyl)phenyl]tripyrrane 
(Compound G), possible dimeric pyrrole di-aldehyde.   A pink solution of the 
compound F (0.80 g, 1.16 mmol) in DMF (10 mL) was stirred for 5 minutes at 0°C under 
anhydrous Ar. Distilled POCl3 (1 mL) was added drop-wise and the resulting mixture 
was stirred for 2.5 hours at rt. Then, 0.5 mL 0.5 M NaOH was added and stirring was 
continued overnight at 80-90°C. The reaction mixture was then cooled to rt, diluted with 
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dichloromethane, and washed three times with water. The organic layer was then dried 
over Na2SO4, filtered and evaporated. The resulting residue was purified via Preparative 
TLC with hexane and ethyl acetate in a 1.5:1 ratio to give (what was thought to be) 
compound G in 13% yield (110 mg). For dimer: MS (LR-ESI) C20H26B10N2O2 (M + Na) 
calcd 457.3, found 457.3. 
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